EXTENSIVE-STAGE SMALL CELL LUNG CANCER

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with advanced small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for four cycles, then continue on two maintenance drugs for u…

This study tests whether a new experimental drug called BMS-986489, when combined with standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small cell lung cancer. The trial will enroll about 530 partici…

This study tests whether adding the experimental drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 adults who have not yet been treated will be randomly assigned to receive either the new com…

This study tests a new drug combination for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer. The treatment combines ifinatamab deruxtecan (I-DXd) with atezolizumab, with or without carboplatin, as a first treatment. About 123 adults will tak…

This study tests a two-step treatment for people with extensive stage small cell lung cancer who have not had treatment before. First, patients receive standard chemotherapy plus immunotherapy. Then, they take two maintenance drugs (durvalumab and ceralasertib) to keep the cancer…

This program offers access to an experimental drug called I-DXd for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments. It is for patients who have no suitable treatment options and cannot join a clinical trial. The goal is to …

This study tests a new drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has come back after chemotherapy. The main goals are to see if it is safe and to measure how the body handles the drug. About 220 adults will…

This early-phase study tests whether combining valemetostat with atezolizumab is safe for people with extensive-stage small cell lung cancer. Researchers will find the best dose of valemetostat and check for side effects. About 24 adults whose cancer has spread will take part. Th…

This early-phase study tests a new drug called ALPS12 in about 122 people with extensive-stage small cell lung cancer that has returned after at least one prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Partici…

This study tests whether adding focused radiation to a standard drug combination (durvalumab plus chemotherapy) can help people with extensive-stage small cell lung cancer live longer without the cancer getting worse. About 49 adults who have not yet been treated for this advance…

This study tests if a drug called trilaciclib, given before chemotherapy, helps people with advanced small cell lung cancer live longer. About 300 participants will receive either trilaciclib or a placebo alongside standard chemo. The goal is to see if the drug improves survival …

This study tests a new treatment for people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread widely. The treatment combines the drug tislelizumab with chemotherapy and radiation to the chest. The goal is to see if this combination can help contro…

This early-stage trial tests two experimental drugs, tarlatamab and AB248, together in people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goal is to see if the combination is safe and to find the best dose. About 380 …

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug combo. About 621 adults who have not yet been treated for this cancer will take part. The goal i…

This study looks at whether a special test (T cell repertoire technology) can predict how well a combination of tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. Researchers will follow 40 patients who have not had treatment befo…